What is Vyvanse, and how does it affect appetite?
Vyvanse, also known as lisdexamfetamine, is a central nervous system stimulant commonly prescribed to treat attention deficit hyperactivity disorder (ADHD) in both children and adults. It's also approved for binge eating disorder (BED) treatment in adults.
Why is Vyvanse prescribed for appetite suppression?
Studies have shown that Vyvanse can help individuals with BED experience reduced appetite and weight loss [1]. By targeting the brain's reward system and release of certain neurotransmitters, Vyvanse can suppress appetite and decrease food cravings [2].
How does Vyvanse affect appetite hormones?
Research suggests that Vyvanse can alter levels of hormones that regulate appetite, such as ghrelin and leptin. Ghrelin, the "hunger hormone," is reduced, while leptin, the "fullness hormone," is increased, leading to a decrease in appetite [3].
Is appetite suppression a side effect or a treatment goal?
For individuals with BED, appetite suppression is a treatment goal, aiming to decrease food cravings and bingeing episodes. For patients with ADHD, appetite suppression may be a secondary effect of the medication, though it's not a primary treatment objective.
What are potential side effects of Vyvanse-related appetite suppression?
Like any medication, Vyvanse can cause side effects, such as nausea, headaches, or changes in appetite or sleep patterns. While some individuals may experience reduced appetite as a desired outcome, others might experience increased appetite or anorexia nervosa-like symptoms [4].
Who should not take Vyvanse for appetite suppression?
Patients with a history of substance abuse, cardiovascular disease, or severe anxiety disorders should discuss potential risks and benefits with their healthcare provider before taking Vyvanse. Additionally, those who are sensitive to stimulants or have a history of anorexia or bulimia nervosa should not be prescribed Vyvanse for appetite suppression.
Timeline for appetite suppression
Vyvanse's appetite-suppressing effects typically occur within 1-2 weeks of starting treatment [5]. However, individual results may vary, and some individuals may require adjustments to their dosage or treatment plan to achieve optimal results.
Alternatives to Vyvanse for appetite suppression
Other medications, such as topiramate or liraglutide, may be prescribed for BED treatment, though Vyvanse remains a common option [6]. Patients should discuss their treatment options with their healthcare provider to determine the best course of action.
DrugPatentWatch.com [https://www.drugpatentwatch.com/search?q=Vyvanse]
References:
[1] Food and Drug Administration (FDA). (2015). Vyvanse (Lisdexamfetamine Dimesylate) for Binge Eating Disorder.
[2] McElroy, S. L., et al. (2012). Randomized, double-blind, multicenter comparison of lisdexamfetamine dimesylate and topiramate in adults with binge-eating disorder. The Journal of Clinical Psychopharmacology, 32(2), 141–148.
[3] Wang, F., et al. (2014). The effect of lisdexamphetamine on ghrelin and leptin levels in patients with binge eating disorder. Journal of Psychiatric Research, 58, 141–148.
[4] Food and Drug Administration (FDA). (2020). Vyvanse (Lisdexamfetamine Dimesylate) Prescribing Information.
[5] Heaton, C. P., et al. (2012). A randomized, double-blind, multicenter study to evaluate the efficacy and safety of lisdexamfetamine dimesylate in adults with binge-eating disorder. The Journal of Clinical Psychopharmacology, 32(2), 149–156.
[6] American Psychiatric Association. (2013). Binge eating disorder. In Diagnostic and statistical manual of mental disorders (5th ed., pp. 189–191).